Actinium Pharmaceuticals
Actinium Pharmaceuticals reported revenue of $0 million in fiscal 2025. Its operating margin was −40,274.4%. Free cash flow was −$25 million. The diluted share count rose 3.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Actinium Pharmaceuticals does
Actinium Pharmaceuticals develops radiation-based cancer drugs, known as radiopharmaceuticals or targeted radiotherapies: a molecule that seeks out a feature of cancer cells carries a radioactive payload straight to them, aiming to kill the tumor while sparing healthy tissue. It is a clinical-stage company, meaning none of its drugs is approved and it has no sales.
Its pipeline has three parts. ATNM-400, still in lab and animal testing, is aimed at solid tumors including prostate, lung and breast cancer. Actimab-A is being studied in solid tumors alongside immune therapies, and in two blood cancers, acute myeloid leukemia (AML) and myelodysplastic syndrome, in partnership with the National Cancer Institute. Iomab-B and Iomab-ACT are meant to prepare patients' bodies before a bone marrow transplant or cell and gene therapy. The company says Actimab-A and Iomab-B are ready for later-stage trials. Many other companies are developing radiopharmaceuticals; Actinium says most are working on a handful of the same targets.
Because it has no products to sell, the company runs at a loss and depends on raising money. It lost $33.9 million in 2025. In March 2026 it had 25 full-time employees.
Its biggest risks, as it describes them
- It has no approved products and no sales, and may never get a drug approved or sell one.
- It has lost money every year and needs more funding, which it may not be able to raise.
- Its clinical trials may fail to show its drug candidates are safe and effective.
- It depends on single outside manufacturers for its trial drug supplies.
- Delays or disruption at the FDA and other agencies, such as during a government shutdown, could slow its trials and approvals.
Income statement
Actinium Pharmaceuticals lost money in fiscal 2025: a net loss of $34 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 78 | 109 | 77 | 73 | 48 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 11.7x | 10.4x | 9.2x | 9.1x | 6.2x |
| Quick ratio | 11.7x | 10.4x | 9.2x | 9.1x | 6.2x |
Cash flow
Projections
Project Actinium Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Actinium Pharmaceuticals reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −58,719.3% | — | — |
| Altman Z'' | −11.33 | −13.17 | −25.07 |
| Accruals ratio | −1.5% | −6.5% | −14.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | — | — |
| F-score | — | — | — |
Compare
Put Actinium Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Actinium Pharmaceuticals | FY25 | — | −40,274.4% | −27,426.7% | — | — | — | |
| Avalo Therapeutics | FY25 | −86.6% | −123,601.7% | — | — | — | 2 | Compare |
| iBio | FY26 | −75.0% | −35,141.0% | −23,796.0% | — | — | — | Compare |
| Inovio Pharmaceuticals | FY25 | −70.0% | −132,871.3% | −136,074.5% | — | — | 0 | Compare |
| Serina Therapeutics | FY25 | 132.1% | −18,478.5% | −13,856.9% | — | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | 1 | 1 | 0 | — | 0 |
| Revenue growth | — | — | — | — | — | — | −10.0% | −92.1% | — | — |
| Gross profit | — | — | — | — | — | 0 | — | — | — | — |
| Research and development | 18 | 18 | 17 | 17 | 16 | 18 | 23 | 39 | 30 | 21 |
| Operating income | −27 | −27 | −24 | −22 | −22 | −25 | −34 | −52 | −42 | −36 |
| Net income | −24 | −27 | −24 | −22 | −22 | −25 | −33 | −49 | −38 | −34 |
| Diluted EPS (US$) | −15.00 | −12.00 | −6.60 | −4.40 | −1.83 | −1.20 | −1.37 | −1.83 | −1.27 | −1.09 |
| Diluted shares (millions) | 2 | 2 | 4 | 5 | 12 | 21 | 24 | 27 | 30 | 31 |
| Cash flow | ||||||||||
| Cash from operations | −21 | −22 | −21 | −22 | −22 | −21 | 9 | −47 | −33 | −25 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −21 | −22 | −21 | −22 | −22 | −21 | 8 | −47 | −33 | −25 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 4 | 4 | 2 | 1 | 1 | 2 | 3 | 4 | 5 | 9 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 20 | 17 | 14 | 9 | 64 | 78 | 109 | 77 | 73 | 48 |
| Debt incl. finance leases | — | — | — | 1 | — | — | — | — | — | — |
| Total assets | 22 | 18 | 15 | 12 | 66 | 80 | 114 | 81 | 77 | 52 |
| Total liabilities | 4 | 5 | 6 | 6 | 5 | 7 | 48 | 45 | 44 | 44 |
| Shareholders' equity | 18 | 14 | 9 | 6 | 61 | 74 | 66 | 36 | 33 | 8 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | 21.3% | — | — | — | — |
| Operating margin | — | — | — | — | — | −2,182.2% | −3,311.1% | −64,098.8% | — | −40,274.4% |
| Net margin | — | — | — | — | — | −2,165.6% | −3,205.5% | −60,269.1% | — | −37,652.2% |
| Free cash flow margin | — | — | — | — | — | −1,835.6% | 803.7% | −58,627.2% | — | −27,426.7% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | 793.7% | −58,719.3% | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −121.7% | −167.9% | −210.4% | −303.0% | −66.3% | −36.7% | −47.2% | −94.9% | −110.6% | −167.0% |
| Return on assets | −99.0% | −130.2% | −142.4% | −164.9% | −56.9% | −33.8% | −33.9% | −49.9% | −48.3% | −52.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |